Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nalu Bio
AddedFeb 16, 2024
UpdatedJun 18, 2026
Nalu Bio

Nalu Bio

Series A

Nalu Bio, a leading biotech firm, innovates CBD production via chemistry, ensuring eco-friendly, pure, and safe cannabinoids.

HQ
San Francisco, CA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Nalu Bio, founded with a mission to revolutionize CBD production, focuses on developing cannabinoids through chemical synthesis rather than traditional plant extraction. This approach ensures the creation of pure, safe, and eco-friendly ingredients for companies seeking sustainable solutions. Nalu Bio's products cater to global consumer packaged goods (CPG) companies, offering cannabinoids for pain, anxiety, sleep, and weight management. Their innovative methods use significantly less land, water, and energy compared to conventional cultivation, aligning with their vision of environmental stewardship.

Notable figures affiliated with Nalu Bio include experts in biotechnology and organic chemistry who drive the company's pioneering research and development. The company has attracted significant investment from leading venture capital firms interested in sustainable biotech innovations. Nalu Bio's key achievements include being ranked as the top CBD producer on ingredient sourcing platforms and setting new standards for purity and quality in cannabinoid production. Their impact is marked by a substantial reduction in resource usage and a commitment to advancing health and wellness through cutting-edge science.

Nalu Bio - Quick Facts

When was Nalu Bio founded?

Nalu Bio was founded in 2019.

Where is Nalu Bio's headquarters located?

Nalu Bio's headquarters is located in San Francisco, CA, US.

When was Nalu Bio's last funding round?

Nalu Bio's most recent funding round was for $12M (USD) in February 2023.

How much has Nalu Bio raised to-date?

As of Feb 28, 2023, Nalu Bio has raised a total of $12.3M (USD).

How many employees does Nalu Bio have?

Nalu Bio has 12 employees as of Feb 5, 2024.

Nalu Bio - Classification

Ownership
  • Private Equity
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cannabinoids
  • CBD
Tags
  • Biotech
  • Cleantech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 17 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 459900Other Miscellaneous Retailers
  • 459990All Other Miscellaneous Retailers
  • 459991Tobacco, Electronic Cigarette, and Other Smoking Supplies Retailers
  • 450000Retail Trade
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 459000Sporting Goods, Hobby, Musical Instrument, Book, and Miscellaneous Retailers
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified